Evaluating congestion markers in patients with acute heart failure and preserved ejection fraction
Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation: Evaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë à Fraction d'éjection préservée
NA · Central Hospital, Nancy, France · NCT04343430
This study is trying to find out if certain tests can help predict the risk of death or being readmitted to the hospital for patients with acute heart failure who have preserved heart function.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 170 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France (other) |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Trial ID | NCT04343430 on ClinicalTrials.gov |
What this trial studies
The AHF-CODE preserved study is a prospective, non-randomized study focusing on patients hospitalized for acute heart failure with preserved ejection fraction. It aims to identify clinical, biological, and ultrasound markers of congestion at the time of hospital discharge that may predict the risk of death or rehospitalization within three months. The study involves various assessments, including Doppler ultrasounds and blood sample analyses, to gather comprehensive data on the patients' conditions. This information could help improve patient management and outcomes post-discharge.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are hospitalized for acute heart failure with preserved ejection fraction.
Not a fit: Patients with severe comorbidities, those on dialysis, or with significant pulmonary issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk stratification and management strategies for patients with acute heart failure.
How similar studies have performed: While similar studies have explored congestion markers in heart failure, this specific approach focusing on preserved ejection fraction is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients hospitalised for acute heart failure. * Patient with preserved ejection fraction (FE ≥ 50%). * Patients considered clinically discharging from hospitalisation for acute heart failure. * Age ≥18 years * Patients having received complete information regarding the study design and having signed their informed consent form. * Patient affiliated to or beneficiary of a social security scheme. Exclusion Criteria: * Comorbidity for which the life expectancy is ≤ 3 months * Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \<15 ml/min/m² at inclusion. * History of lobectomy or pneumonectomy lung surgery * Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc. * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Adult person who is unable to give consent * Person deprived of liberty by a judicial or administrative decision, * Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Where this trial is running
Vandœuvre-lès-Nancy
- CHRU de Nancy — Vandœuvre-lès-Nancy, France (RECRUITING)
Study contacts
- Study coordinator: Nicolas GIRERD, MD,PhD
- Email: n.girerd@chru-nancy.fr
- Phone: + 33 3 83 15 73 22
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Heart Failure